Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Tertiary lymphoid structures are formations that occur outside of the lymphatic system. They contain immune cells and are similar in structure and function to lymph nodes and other lymphoid structures.
A new study by researchers from the University of Pennsylvania shows that experimental immunotherapy can temporarily reprogram the immune cells of patients.
UC San Francisco researchers have defined 12 classes of “immune archetypes” to identify cancer tumors based on data from over 300 patient tumors.
A novel immunotherapy strategy using in vivo generation of transient engineered chimeric antigen receptor (CAR) T cells, through the delivery of modified mRNA, can reduce fibrosis and restore cardiac function in a mouse model of heart failure, researchers report.
A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.
Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.
In the last 10 years, immunotherapy has been used to save the lives of several cancer patients with lung cancer.
A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME) was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab (Tecentriq) to chemotherapy as neoadjuvant treatment for patients with early high-risk and locally advanced triple negative breast cancer (TNBC), according to results presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.
In recent years, tumor immunotherapy has emerged as a highly promising and much-touted oncological approach.
Lunaphore today announced new research from collaborators at the University of Birmingham.
Immunotherapies are exhibiting better clinical benefit in the treatment of numerous cancers, particularly when used along with chemotherapy.
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors.
T cells communicate with other cells in the body in search of infections or diseases. This crosstalk relies on specialized receptors known as T cell receptors that recognize foreign molecular fragments from an infection or cancer that are presented for detection by particular molecules called major histocompatibility complex (MHC) or MHC-like.
Under the right circumstances, the body's T cells can detect and destroy cancer cells. However, in most cancer patients, T cells become disarmed once they enter the environment surrounding a tumor.
Researchers utilized the power of nanotechnology to identify a novel means that cancer cells use to disarm their would-be cellular attackers.
Recent research led to a very effective technique to create many immune cells particularly engineered to identify neoantigens.
Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.
Scientists from the Wistar Institute revealed how major features on the surface of HIV-infected cells help the disease avoid detection by the immune system.
Researchers have developed a model that could predict early on in treatment whether cancer patients will respond to immunotherapy, according to a report published today in eLife.
Biognosys today announces the launch of its next-generation blood biomarker discovery solution, which will be offered as a contract research service.